Table 5. Cox proportional hazard model for risk of disease endpoints according to CKD stages (n = 352).
CKD progression | Unadjusted | Model 1 | Model 2 |
G2 | 5.18 (0.47–57.13) | 4.67 (0.41–53.64) | 16.38 (0.62–435.49) |
G3a | ref | ref | ref |
G3b | 1.33 (0.12–14.73) | 1.49 (0.13–17.24) | 3.81 (0.19–75.40) |
G4–G5 | 4.63 (0.54–39.63) | 5.94 (0.63–56.01) | 8.21 (0.61–110.28) |
Cardiovascular events | Unadjusted | Model 1 | Model 2 |
G2 | 0 | 0 | 0 |
G3a | ref | ref | ref |
G3b | 1.22 (0.45–3.29) | 0.67 (0.24–1.91) | 0.67 (0.23–1.95) |
G4–G5 | 1.69 (0.63–4.58) | 0.70 (0.23–2.14) | 0.88 (0.26–2.94) |
All-cause death | Unadjusted | Model 1 | Model 2 |
G2 | 2.55 (0.16–40.73) | 4.81 (0.29–78.90) | 5.93 (0.33–105.69) |
G3a | ref | ref | ref |
G3b | 1.35 (0.12–14.91) | 0.92 (0.08–10.51) | 0.94 (0.08–11.36) |
G4–G5 | 12.86 (1.69–97.84) | 7.42 (0.87–63.50) | 4.47(0.47–42.21) |
Data are presented as hazard ratios (95% confidence intervals).
Model 1: Adjusted by age, gender, hypertension, diabetes, and history of CVD. Model 2, Adjusted by Model 1, hemoglobin, serum albumin, and the use of RAAS inhibitor. Abbreviations: CKD, chronic kidney disease.